Ascensia Diabetes Care
Private Company
Total funding raised: $300M
Overview
Ascensia Diabetes Care is a global, pure-play diabetes company focused on diagnostics and digital health solutions. It operates as a subsidiary of PHC Holdings, having been formed through the acquisition of Bayer Diabetes Care in 2016. The company's core business revolves around its CONTOUR brand of blood glucose monitoring systems and complementary digital tools for diabetes management. With a strong commercial footprint and a patient-centric approach, Ascensia aims to innovate within the diabetes care continuum while integrating ESG principles into its corporate strategy.
Technology Platform
Blood glucose monitoring (BGM) systems and integrated digital health platforms for diabetes management. Core technology focuses on high-accuracy meter systems (CONTOUR portfolio) and complementary software solutions for data tracking and trend analysis.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Ascensia competes in a crowded diabetes diagnostics market against major players like Roche (Accu-Chek), Abbott (FreeStyle), LifeScan (OneTouch), and emerging CGM leaders such as Dexcom and Medtronic. Its position relies on brand heritage, accuracy, and a global distribution network, but it faces pressure from both low-cost alternatives and innovative sensor-based technologies.